Spero Therapeutics Q3 net loss narrows

Spero Therapeutics

13/11/2025 21:24

Overview

Spero Q3 net loss narrows

Spero expects cash reserves to fund operations into 2028

Outlook

Spero expects cash reserves to fund operations into 2028

Result Drivers

REVENUE DECLINE - Decreased collaboration revenue with GSK and reduced grant revenue led to lower total revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.13
Q3 Net Income
Beat
-$7.38 mln
-$22 mln (1 Analyst)
Q3 Income From Operation
-$7.92 mln
Q3 Operating Expenses
$13.36 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Spero Therapeutics Inc is $5.00, about 46.8% above its November 12 closing price of $2.66

Press Release: ID:nGNX21XMV8

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)